CYTOKINETICS, INCORPORATED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 65.34 USD | +0.83% |
|
-3.27% | -21.74% |
| Apr. 26 | Cytokinetics Appoints Sung Lee as CFO | MT |
| Apr. 26 | Cytokinetics, Incorporated Appoints Sung H. Lee as Executive Vice President, Effective as of May 8, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 627.7 | 1,471 | 3,823 | 4,336 | 8,186 | 6,846 | - | - |
| Enterprise Value (EV) 1 | 531.8 | 1,142 | 3,495 | 4,163 | 8,179 | 6,570 | 6,240 | 6,375 |
| P/E ratio | -5.03 x | -10.5 x | -16.3 x | -10.6 x | -15.3 x | -14.8 x | -20.5 x | -64.8 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 23.4 x | 26.3 x | 54.3 x | 45.8 x | 1,087 x | 565 x | 41.5 x | 13.4 x |
| EV / Revenue | 19.8 x | 20.5 x | 49.6 x | 44 x | 1,086 x | 543 x | 37.8 x | 12.4 x |
| EV / EBITDA | -5.45 x | -12.4 x | -19 x | -13.1 x | -16.9 x | -15.8 x | -24 x | -149 x |
| EV / FCF | - | - | -18.3 x | -13.4 x | -19.7 x | -14.6 x | -16 x | -27.1 x |
| FCF Yield | - | - | -5.48% | -7.47% | -5.08% | -6.87% | -6.25% | -3.7% |
| Price to Book | -57.4 x | 13 x | 15.8 x | -40.3 x | -22 x | -12.2 x | -48.7 x | -16.6 x |
| Nbr of stocks (in thousands) | 59,161 | 70,779 | 83,883 | 94,631 | 98,054 | 104,774 | - | - |
| Reference price 2 | 10.61 | 20.78 | 45.58 | 45.82 | 83.49 | 65.34 | 65.34 | 65.34 |
| Announcement Date | 3/3/20 | 2/25/21 | 2/24/22 | 3/1/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 26.87 | 55.83 | 70.43 | 94.59 | 7.53 | 12.11 | 165 | 512.2 |
| EBITDA 1 | -97.57 | -92.11 | -184 | -318.4 | -484.3 | -416.6 | -260.2 | -42.85 |
| EBIT 1 | -98.87 | -93.94 | -186.3 | -324.2 | -496.2 | -448 | -339.7 | -114.7 |
| Operating Margin | -367.97% | -168.27% | -264.54% | -342.75% | -6,589.71% | -3,699.61% | -205.81% | -22.4% |
| Earnings before Tax (EBT) 1 | -121.7 | -127.3 | -215.3 | -389 | -526.2 | -469.9 | -360.4 | -150.8 |
| Net income 1 | -121.7 | -127.3 | -215.3 | -389 | -526.2 | -465.6 | -353 | -134.2 |
| Net margin | -452.93% | -228% | -305.72% | -411.21% | -6,988.63% | -3,845.09% | -213.91% | -26.2% |
| EPS 2 | -2.110 | -1.970 | -2.800 | -4.330 | -5.450 | -4.414 | -3.180 | -1.008 |
| Free Cash Flow 1 | - | - | -191.4 | -310.9 | -415.7 | -451.2 | -389.8 | -235.6 |
| FCF margin | - | - | -271.76% | -328.64% | -5,521.24% | -3,726.84% | -236.21% | -46.01% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/3/20 | 2/25/21 | 2/24/22 | 3/1/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 7.42 | 5.437 | 55.6 | 1.148 | 88.97 | 2.515 | 1.957 | 4.613 | 0.867 | 0.378 | 1.672 | 0.9066 | 0.8853 | 4.421 | 0.9213 | - |
| EBITDA | - | -68.74 | -20.97 | -76.52 | -9.467 | -107 | -125.4 | -122.6 | -120.2 | -120.4 | -121.1 | - | - | - | - | - |
| EBIT 1 | -62.72 | -69.2 | -21.7 | -77.86 | -10.87 | -108.4 | -127 | -124.5 | -122 | -122.3 | -127.4 | -115.6 | -112.8 | -106.9 | -111.9 | -122 |
| Operating Margin | -845.28% | -1,272.78% | -39.04% | -6,781.97% | -12.22% | -4,311.77% | -6,491.06% | -2,698.31% | -14,077.16% | -32,345.24% | -7,620.69% | -12,753.22% | -12,745.99% | -2,416.96% | -12,140.89% | - |
| Earnings before Tax (EBT) 1 | -80.19 | -76.09 | -30.57 | -89.44 | -19.82 | -142.3 | -137.4 | -131.3 | -128.6 | -129.4 | -136.9 | -122.3 | -120.4 | -113.9 | -119.3 | -122 |
| Net income 1 | -80.19 | -76.09 | -30.57 | -89.44 | -19.82 | -142.3 | -137.4 | -131.3 | -128.6 | -129.4 | -136.9 | -119.3 | -118.2 | -113.8 | -119.9 | -122 |
| Net margin | -1,080.73% | -1,399.41% | -54.98% | -7,791.38% | -22.28% | -5,658.45% | -7,019.93% | -2,846.07% | -14,837.02% | -34,238.62% | -8,187.56% | -13,157.74% | -13,351.43% | -2,574.12% | -13,018.59% | - |
| EPS 2 | - | -0.9500 | -0.3600 | -1.050 | -0.2300 | -1.520 | -1.450 | -1.380 | -1.340 | -1.350 | -1.380 | -1.149 | -1.124 | -1.081 | -1.081 | -1.200 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/6/20 | 11/3/21 | 2/24/22 | 5/4/22 | 8/4/22 | 11/3/22 | 3/1/23 | 5/4/23 | 8/3/23 | 11/2/23 | 2/27/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 95.9 | 328 | 329 | 173 | 7.45 | 276 | 606 | 471 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -191 | -311 | -416 | -451 | -390 | -236 |
| ROE (net income / shareholders' equity) | - | -112% | -121% | -572% | - | -92.7% | -31.3% | - |
| ROA (Net income/ Total Assets) | - | - | -31.3% | -41.9% | -57.2% | -80.7% | -86.9% | -46.6% |
| Assets 1 | - | - | 687.6 | 928 | 919.5 | 576.6 | 406.4 | 288.1 |
| Book Value Per Share 2 | -0.1800 | 1.600 | 2.880 | -1.140 | -3.800 | -5.350 | -1.340 | -3.930 |
| Cash Flow per Share 2 | - | - | - | -3.330 | -4.290 | -2.940 | -1.520 | - |
| Capex 1 | - | - | 48.9 | 11.3 | 1.42 | 6.8 | 24.5 | 48.2 |
| Capex / Sales | - | - | 69.39% | 11.98% | 18.8% | 56.13% | 14.86% | 9.41% |
| Announcement Date | 3/3/20 | 2/25/21 | 2/24/22 | 3/1/23 | 2/27/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
20
Last Close Price
65.34
USD
Average target price
91.34
USD
Spread / Average Target
+39.79%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.74% | 6.85B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- CYTK Stock
- Financials Cytokinetics, Incorporated
